Distribution and clinical impact of molecular subtypes with dark zone signature of DLBCL in a Japanese real-world study
© 2023 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved..
The distribution and clinical impact of cell-of-origin (COO) subtypes of diffuse large B-cell lymphoma (DLBCL) outside Western countries remain unknown. Recent literature also suggests that there is an additional COO subtype associated with the germinal center dark zone (DZ) that warrants wider validation to generalize clinical relevance. Here, we assembled a cohort of Japanese patients with untreated DLBCL and determined the refined COO subtypes, which include the DZ signature (DZsig), using the NanoString DLBCL90 assay. To compare the distribution and clinical characteristics of the molecular subtypes, we used a data set from the cohort of British Columbia Cancer (BCC) (n = 804). Through the 1050 patient samples on which DLBCL90 assay was successfully performed in our cohort, 35%, 45%, and 6% of patients were identified to have germinal center B-cell-like (GCB) DLBCL, activated B-cell-like (ABC) DLBCL, and DZsig-positive (DZsigpos) DLBCL, respectively, with the highest prevalence of ABC-DLBCL, differing significantly from the BCC result (P < .001). GCB-DLBCL, ABC-DLBCL, and DZsigpos-DLBCL were associated with 2-year overall survival rates of 88%, 75%, and 66%, respectively (P < .0001), with patients with DZsigpos-DLBCL having the poorest prognosis. In contrast, GCB-DLBCL without DZsig showed excellent outcomes after rituximab-containing immunochemotherapy. DZsigpos-DLBCL was associated with the significant enrichment of tumors with CD10 expression, concurrent MYC/BCL2 expression, and depletion of microenvironmental components (all, P < .05). These results provide evidence of the distinct distribution of clinically relevant molecular subtypes in Japanese DLBCL and that refined COO, as measured by the DLBCL90 assay, is a robust prognostic biomarker that is consistent across geographical areas.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:7 |
|---|---|
| Enthalten in: |
Blood advances - 7(2023), 24 vom: 26. Dez., Seite 7459-7470 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Urata, Tomohiro [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
4F4X42SYQ6 |
|---|
| Anmerkungen: |
Date Completed 16.12.2023 Date Revised 10.01.2024 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1182/bloodadvances.2023010402 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM360521398 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM360521398 | ||
| 003 | DE-627 | ||
| 005 | 20240114233736.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1182/bloodadvances.2023010402 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1256.xml |
| 035 | |a (DE-627)NLM360521398 | ||
| 035 | |a (NLM)37552496 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Urata, Tomohiro |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Distribution and clinical impact of molecular subtypes with dark zone signature of DLBCL in a Japanese real-world study |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 16.12.2023 | ||
| 500 | |a Date Revised 10.01.2024 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved. | ||
| 520 | |a The distribution and clinical impact of cell-of-origin (COO) subtypes of diffuse large B-cell lymphoma (DLBCL) outside Western countries remain unknown. Recent literature also suggests that there is an additional COO subtype associated with the germinal center dark zone (DZ) that warrants wider validation to generalize clinical relevance. Here, we assembled a cohort of Japanese patients with untreated DLBCL and determined the refined COO subtypes, which include the DZ signature (DZsig), using the NanoString DLBCL90 assay. To compare the distribution and clinical characteristics of the molecular subtypes, we used a data set from the cohort of British Columbia Cancer (BCC) (n = 804). Through the 1050 patient samples on which DLBCL90 assay was successfully performed in our cohort, 35%, 45%, and 6% of patients were identified to have germinal center B-cell-like (GCB) DLBCL, activated B-cell-like (ABC) DLBCL, and DZsig-positive (DZsigpos) DLBCL, respectively, with the highest prevalence of ABC-DLBCL, differing significantly from the BCC result (P < .001). GCB-DLBCL, ABC-DLBCL, and DZsigpos-DLBCL were associated with 2-year overall survival rates of 88%, 75%, and 66%, respectively (P < .0001), with patients with DZsigpos-DLBCL having the poorest prognosis. In contrast, GCB-DLBCL without DZsig showed excellent outcomes after rituximab-containing immunochemotherapy. DZsigpos-DLBCL was associated with the significant enrichment of tumors with CD10 expression, concurrent MYC/BCL2 expression, and depletion of microenvironmental components (all, P < .05). These results provide evidence of the distinct distribution of clinically relevant molecular subtypes in Japanese DLBCL and that refined COO, as measured by the DLBCL90 assay, is a robust prognostic biomarker that is consistent across geographical areas | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a Rituximab |2 NLM | |
| 650 | 7 | |a 4F4X42SYQ6 |2 NLM | |
| 700 | 1 | |a Naoi, Yusuke |e verfasserin |4 aut | |
| 700 | 1 | |a Jiang, Aixiang |e verfasserin |4 aut | |
| 700 | 1 | |a Boyle, Merrill |e verfasserin |4 aut | |
| 700 | 1 | |a Sunami, Kazutaka |e verfasserin |4 aut | |
| 700 | 1 | |a Imai, Toshi |e verfasserin |4 aut | |
| 700 | 1 | |a Nawa, Yuichiro |e verfasserin |4 aut | |
| 700 | 1 | |a Hiramatsu, Yasushi |e verfasserin |4 aut | |
| 700 | 1 | |a Yamamoto, Kazuhiko |e verfasserin |4 aut | |
| 700 | 1 | |a Fujii, Soichiro |e verfasserin |4 aut | |
| 700 | 1 | |a Yoshida, Isao |e verfasserin |4 aut | |
| 700 | 1 | |a Yano, Tomofumi |e verfasserin |4 aut | |
| 700 | 1 | |a Chijimatsu, Ryota |e verfasserin |4 aut | |
| 700 | 1 | |a Murakami, Hiroyuki |e verfasserin |4 aut | |
| 700 | 1 | |a Ikeuchi, Kazuhiro |e verfasserin |4 aut | |
| 700 | 1 | |a Kobayashi, Hiroki |e verfasserin |4 aut | |
| 700 | 1 | |a Tani, Katsuma |e verfasserin |4 aut | |
| 700 | 1 | |a Ujiie, Hideki |e verfasserin |4 aut | |
| 700 | 1 | |a Inoue, Hirofumi |e verfasserin |4 aut | |
| 700 | 1 | |a Tomida, Shuta |e verfasserin |4 aut | |
| 700 | 1 | |a Yamamoto, Akira |e verfasserin |4 aut | |
| 700 | 1 | |a Kondo, Takumi |e verfasserin |4 aut | |
| 700 | 1 | |a Fujiwara, Hideaki |e verfasserin |4 aut | |
| 700 | 1 | |a Asada, Noboru |e verfasserin |4 aut | |
| 700 | 1 | |a Nishimori, Hisakazu |e verfasserin |4 aut | |
| 700 | 1 | |a Fujii, Keiko |e verfasserin |4 aut | |
| 700 | 1 | |a Fujii, Nobuharu |e verfasserin |4 aut | |
| 700 | 1 | |a Matsuoka, Ken-Ichi |e verfasserin |4 aut | |
| 700 | 1 | |a Sawada, Keisuke |e verfasserin |4 aut | |
| 700 | 1 | |a Momose, Shuji |e verfasserin |4 aut | |
| 700 | 1 | |a Tamaru, Jun-Ichi |e verfasserin |4 aut | |
| 700 | 1 | |a Nishikori, Asami |e verfasserin |4 aut | |
| 700 | 1 | |a Sato, Yasuharu |e verfasserin |4 aut | |
| 700 | 1 | |a Yoshino, Tadashi |e verfasserin |4 aut | |
| 700 | 1 | |a Maeda, Yoshinobu |e verfasserin |4 aut | |
| 700 | 1 | |a Scott, David W |e verfasserin |4 aut | |
| 700 | 1 | |a Ennishi, Daisuke |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Blood advances |d 2016 |g 7(2023), 24 vom: 26. Dez., Seite 7459-7470 |w (DE-627)NLM268683263 |x 2473-9537 |7 nnns |
| 773 | 1 | 8 | |g volume:7 |g year:2023 |g number:24 |g day:26 |g month:12 |g pages:7459-7470 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1182/bloodadvances.2023010402 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 7 |j 2023 |e 24 |b 26 |c 12 |h 7459-7470 | ||